Role of Epigenetic Modification and Immunomodulation in a Murine Prostate Cancer Model

Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer

(2015) J. Wang et al.   CLINICAL & EXPERIMENTAL METASTASIS

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

(2015) E. A. Chong et al.   CLINICAL CANCER RESEARCH

Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy

(2015) Rakesh Singal et al.   Clinical Genitourinary Cancer

Expression and clinical significance of Centrosomal protein 55 (CEP55) in human urinary bladder transitional cell carcinoma

(2015) P.K. Singh et al.   IMMUNOBIOLOGY

Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

(2015) Daniel P Petrylak et al.   LANCET ONCOLOGY

Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells

(2014) Andrea Acebes-Huerta et al.   Biomed Research International

Lenalidomide Monotherapy in Chemotherapy-Naive, Castration-Resistant Prostate Cancer Patients: Final Results of a Phase II Study

(2013) Chadi Nabhan et al.   Clinical Genitourinary Cancer

Age-Specific Gene Expression Signatures for Breast Tumors and Cross-Species Conserved Potential Cancer Progression Markers in Young Women

(2013) Dilek Colak et al.   PLoS One

The Role of IMiDs Alone or in Combination in Prostate Cancer

(2012) Chadi Nabhan et al.   Clinical Genitourinary Cancer

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

(2012) G Ramsingh et al.   LEUKEMIA

Cancer/Testis antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy

(2011) Takumi Shiraishi et al.   Journal of Translational Medicine

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia

(2011) D A Pollyea et al.   LEUKEMIA

The biology of cancer testis antigens: Putative function, regulation and therapeutic potential

(2011) Elisabetta Fratta et al.   Molecular Oncology

Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer

(2011) Daniel J. Zabransky et al.   PROSTATE

Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo

(2011) J.Y. Henry et al.   PROSTATE

Docetaxel-based combination therapy for castration-resistant prostate cancer

(2010) M. D. Galsky et al.   ANNALS OF ONCOLOGY

A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy

(2010) P. Mathew et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dendritic Cell-Based Immunotherapy for Prostate Cancer

(2010) Hanka Jähnisch et al.   Clinical & Developmental Immunology

The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma

(2010) Satoko Inoda et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes

(2010) Mikkael A. Sekeres et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergy of 5-aza-2′-deoxycytidine (DAC) and paclitaxel in both androgen-dependent and -independent prostate cancer cell lines

(2009) Donghao Shang et al.   CANCER LETTERS

Mechanism of action of lenalidomide in hematological malignancies

(2009) Venumadhav Kotla et al.   Journal of Hematology & Oncology